Morningside Ventures has led a $30m series A round for Emory University spinout Meissa Vaccines, a current resident in Johnson & Johnsons’ JLabs incubator.
Meissa Vaccines, a US-based developer of vaccines for viral respiratory infections based on research at Emory University, completed a $30m series A round yesterday led by Morningside Ventures.
Founded in 2014, Meissa’s platform exploits synthetic biology and genetic engineering to rapidly generate vaccines for respiratory conditions. The spinout expects its vaccines will be safer and induce a more efficient immune response than natural pathogens.
Meissa advances research by CEO Martin Moore, associate professor at Emory University and director…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
